Table 1 EUTOS score and outcome... | American Society of Hematology

Table 1

EUTOS score and outcome

Parameter	Category	Overall (N = 465)	Low EUTOS score, 427 (92%)	High EUTOS score, 38 (8%)	P
CCyR, %	Overall (evaluable = 454)	92	93	81	.02
	Imatinib	90	91	82	.27
	400 mg	87	86	100	1.0
	800 mg	91	92	79	.08
	2nd-TKI	95	96	80	.03
MMR, %	Overall (evaluable = 452)	85	85	81	.48
	Imatinib	84	85	82	.76
	400 mg	78	77	100	1.0
	800 mg	86	87	79	.30
	2nd-TKI	86	86	80	.46
3-year EFS, %	Overall	86	86	86	.71
	Imatinib	84	84	77	.20
	400 mg	80	81	50	.34
	800 mg	85	85	83	.29
	2nd-TKI	91	90	100	.16
3-year TFS, %	Overall	95	95	97	.51
	Imatinib	94	93	94	.33
	400 mg	89	90	67	.47
	800 mg	95	95	100	.46
	2nd-TKI	99	99	100	.53
3-year OS, %	Overall	97	97	100	.88
	Imatinib	96	96	100	.75
	400 mg	93	92	100	.34
	800 mg	97	97	100	.32
	2nd-TKI	99	97	100	.64

Parameter	Category	Overall (N = 465)	Low EUTOS score, 427 (92%)	High EUTOS score, 38 (8%)	P
CCyR, %	Overall (evaluable = 454)	92	93	81	.02
	Imatinib	90	91	82	.27
	400 mg	87	86	100	1.0
	800 mg	91	92	79	.08
	2nd-TKI	95	96	80	.03
MMR, %	Overall (evaluable = 452)	85	85	81	.48
	Imatinib	84	85	82	.76
	400 mg	78	77	100	1.0
	800 mg	86	87	79	.30
	2nd-TKI	86	86	80	.46
3-year EFS, %	Overall	86	86	86	.71
	Imatinib	84	84	77	.20
	400 mg	80	81	50	.34
	800 mg	85	85	83	.29
	2nd-TKI	91	90	100	.16
3-year TFS, %	Overall	95	95	97	.51
	Imatinib	94	93	94	.33
	400 mg	89	90	67	.47
	800 mg	95	95	100	.46
	2nd-TKI	99	99	100	.53
3-year OS, %	Overall	97	97	100	.88
	Imatinib	96	96	100	.75
	400 mg	93	92	100	.34
	800 mg	97	97	100	.32
	2nd-TKI	99	97	100	.64

Sixty-seven patients (94%) receiving standard-dose imatinib, 189 (91%) receiving high-dose imatinib, and 171 (92%) receiving second-generation TKIs were in the low EUTOS score category.

2nd-TKI indicates second-generation TKI.

View Large

This Feature Is Available To Subscribers Only